Cancer vaccine - Russian Biotechnologies
Latest Information Update: 31 Dec 2021
Price :
$50 *
At a glance
- Originator Russian Biotechnologies
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 06 Apr 2006 Phase-II clinical trials in Malignant melanoma in Russia (SC)